Human carbonyl reductases

Current Drug Metabolism

Volumn 11, Issue 8, 2010, Pages 639-658

  Malátková, Petra ^a,b   Maser, Edmund ^a,b   Wsól, Vladimír ^a,b  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

CBR1; CBR3; CBR4; Detoxification; Endogenous substrates; Metabolism; Polymorphism; Regulation; Xenobiotics

Indexed keywords

1,2 NAPHTHOQUINONE; 1,4 NAPHTHOQUINONE; 4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANONE; BROMPERIDOL; CARBONYL REDUCTASE; DAUNORUBICIN; DOXORUBICIN; HALOPERIDOL; ISATIN; MENADIONE; METYRAPONE; ORACIN; PHENANTHRENEQUINONE; PROSTAGLANDIN; QUINONE DERIVATIVE; TIMIPERONE; XENOBIOTIC AGENT;

ARTICLE; CATALYSIS; DISEASE ASSOCIATION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME POLYMORPHISM; ENZYME STRUCTURE; ENZYME SUBSTRATE; HUMAN; NEOPLASM; NONHUMAN; PHYSIOLOGY; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; TISSUE SPECIFICITY; TRANSCRIPTION REGULATION;

ALCOHOL OXIDOREDUCTASES; ANIMALS; GENE EXPRESSION; HUMANS; MITOCHONDRIAL PROTEINS; NAD(P)H DEHYDROGENASE (QUINONE); POLYMORPHISM, GENETIC; XENOBIOTICS;

EID: 79952347015     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920010794233530     Document Type: Article

References (155)

1. Oppermann, U. Carbonyl reductases: the complex relationships of mammalian carbonyl-and quinone-reducing enzymes and their role in physiology. Annu. Rev. Pharmacol. Toxicol., 2007, 47, 293-322.
2. Matsunaga, T.; Shintani, S.; Hara, A. Multiplicity of mammalian reductases for xenobiotic carbonyl compounds. Drug Metab Pharmacokinet., 2006, 21(1), 1-18.
3. Penning, T. M.; Drury, J. E. Human aldo-keto reductases: Function, gene regulation, and single nucleotide polymorphisms. Arch. Biochem. Biophys., 2007, 464(2), 241-250. (Pubitemid 47214569)
4. Hoffmann, F.; Maser, E. Carbonyl reductases and pluripotent hydroxysteroid dehydrogenases of the short-chain dehydrogenase/reductase superfamily. Drug Metab. Rev., 2007, 39(1), 87-144.
5. Pilka, E. S.; Niesen, F. H.; Lee, W. H.; El-Hawari, Y.; Dunford, J. E.; Kochan, G.; Wsol, V.; Martin, H. J.; Maser, E.; Oppermann, U. Structural basis for substrate specificity in human monomeric carbonyl reductases. PLoS. One, 2009, 4(10), e7113.
6. Kallberg, Y.; Persson, B. Prediction of coenzyme specificity in dehydrogenases/reductases. A hidden Markov model-based method and its application on complete genomes. FEBS J, 2006, 273(6), 1177-1184. (Pubitemid 43345038)
7. Persson, B.; Kallberg, Y.; Bray, J. E.; Bruford, E.; Dellaporta, S. L.; Favia, A. D.; Duarte, R. G.; Jornvall, H.; Kavanagh, K. L.; Kedishvili, N.; Kisiela, M.; Maser, E.; Mindnich, R.; Orchard, S.; Penning, T. M.; Thornton, J. M.; Adamski, J.; Oppermann, U. The SDR (short-chain dehydrogenase/reductase and related enzymes) nomenclature initiative. Chem. Biol. Interact., 2009, 178 (1-3), 94-98.
8. Nakanishi, M.; Deyashiki, Y.; Nakayama, T.; Sato, K.; Hara, A. Cloning and sequence analysis of a cDNA encoding tetrameric carbonyl reductase of pig lung. Biochem. Biophys. Res. Commun., 1993, 194(3), 1311-1316. (Pubitemid 23255025)
9. Nakanishi, M.; Deyashiki, Y.; Ohshima, K.; Hara, A. Cloning, expression and tissue distribution of mouse tetrameric carbonyl reductase. Identity with an adipocyte 27-kDa protein. Eur. J. Biochem., 1995, 228(2), 381-387.
10. Miura, T.; Nishinaka, T.; Terada, T. Importance of the substratebinding loop region of human monomeric carbonyl reductases in catalysis and coenzyme binding. Life Sci., 2009, 85 (7-8), 303-308.
11. El-Kabbani, O.; Carbone, V.; Darmanin, C.; Ishikura, S.; Hara, A. Structure of the tetrameric form of human L-Xylulose reductase: probing the inhibitor-binding site with molecular modeling and site-directed mutagenesis. Proteins, 2005, 60(3), 424-432. (Pubitemid 41065096)
12. Miura, T.; Itoh, Y.; Takada, M.; Tsutsui, H.; Yukimura, T.; Nishinaka, T.; Terada, T. Investigation of the role of the amino acid residue at position 230 for catalysis in monomeric carbonyl reductase 3. Chem. Biol. Interact., 2009, 178 (1-3), 211-214.
13. Miura, T.; Nishinaka, T.; Terada, T. Different functions between human monomeric carbonyl reductase 3 and carbonyl reductase 1. Mol. Cell Biochem., 2008, 315 (1-2), 113-121.
14. El-Hawari, Y.; Favia, A. D.; Pilka, E. S.; Kisiela, M.; Oppermann, U.; Martin, H. J.; Maser, E. Analysis of the substrate-binding site of human carbonyl reductases CBR1 and CBR3 by site-directed mutagenesis. Chem. Biol. Interact., 2009, 178 (1-3), 234-241.
15. Endo, S.; Matsunaga, T.; Kitade, Y.; Ohno, S.; Tajima, K.; El-Kabbani, O.; Hara, A. Human carbonyl reductase 4 is a mitochondrial NADPH-dependent quinone reductase. Biochem. Biophys. Res. Commun., 2008, 377(4), 1326-1330.
16. Chen, Z.; Kastaniotis, A. J.; Miinalainen, I. J.; Rajaram, V.; Wierenga, R. K.; Hiltunen, J. K. 17beta-hydroxysteroid dehydrogenase type 8 and carbonyl reductase type 4 assemble as a ketoacyl reductase of human mitochondrial FAS. FASEB J., 2009, 23(11), 3682-3691.
17. Wermuth, B. Purification and properties of an NADPH-dependent carbonyl reductase from human brain. Relationship to prostaglandin 9-ketoreductase and xenobiotic ketone reductase. J. Biol. Chem., 1981, 256(3), 1206-1213. (Pubitemid 11157222)
18. Park, Y. S.; Heizmann, C. W.; Wermuth, B.; Levine, R. A.; Steinerstauch, P.; Guzman, J.; Blau, N. Human carbonyl and aldose reductases: new catalytic functions in tetrahydrobiopterin biosynthesis. Biochem. Biophys. Res. Commun., 1991, 175(3), 738-744.
19. Schieber, A.; Frank, R. W.; Ghisla, S. Purification and properties of prostaglandin 9-ketoreductase from pig and human kidney. Identity with human carbonyl reductase. Eur. J. Biochem., 1992, 206(2), 491-502.
20. Maser, E. Neuroprotective role for carbonyl reductase? Biochem. Biophys. Res. Commun., 2006, 340(4), 1019-1022. (Pubitemid 43083380)
21. Forrest, G. L.; Akman, S.; Krutzik, S.; Paxton, R. J.; Sparkes, R. S.; Doroshow, J.; Felsted, R. L.; Glover, C. J.; Mohandas, T.; Bachur, N. R. Induction of a human carbonyl reductase gene located on chromosome 21. Biochim. Biophys. Acta, 1990, 1048 (2-3), 149-155. (Pubitemid 20100777)
22. Tobin, J. E.; Cui, J.; Wilk, J. B.; Latourelle, J. C.; Laramie, J. M.; McKee, A. C.; Guttman, M.; Karamohamed, S.; DeStefano, A. L.; Myers, R. H. Sepiapterin reductase expression is increased in Parkinson's disease brain tissue. Brain Res., 2007, 1139, 42-47.
23. Balcz, B.; Kirchner, L.; Cairns, N.; Fountoulakis, M.; Lubec, G. Increased brain protein levels of carbonyl reductase and alcohol dehydrogenase in Down syndrome and Alzheimer's disease. J. Neural Transm. Suppl, 2001, (61), 193-201. (Pubitemid 38085082)
24. Bergholdt, R.; Nerup, J.; Pociot, F. Fine mapping of a region on chromosome 21q21.11-q22.3 showing linkage to type 1 diabetes. J. Med. Genet., 2005, 42(1), 17-25. (Pubitemid 40187116)
25. Ismail, E.; Al-Mulla, F.; Tsuchida, S.; Suto, K.; Motley, P.; Harrison, P. R.; Birnie, G. D. Carbonyl reductase: a novel metastasis-modulating function. Cancer Res., 2000, 60(5), 1173-1176. (Pubitemid 30151976)
26. Ohkura-Hada, S.; Kondoh, N.; Hada, A.; Arai, M.; Yamazaki, Y.; Shindoh, M.; Kitagawa, Y.; Takahashi, M.; Ando, T.; Sato, Y.; Yamamoto, M. Carbonyl Reductase 3 (CBR3) Mediates 9-cisretinoic acid-induced cytostatis and is a potential prognostic marker for oral malignancy. Open. Dent. J., 2008, 2, 78-88.
27. Espana, L.; Martin, B.; Aragues, R.; Chiva, C.; Oliva, B.; Andreu, D.; Sierra, A. Bcl-x (L)-mediated changes in metabolic pathways of breast cancer cells: from survival in the blood stream to organspecific metastasis. Am. J. Pathol., 2005, 167(4), 1125-1137. (Pubitemid 41416263)
28. Suto, K.; Kajihara-Kano, H.; Yokoyama, Y.; Hayakari, M.; Kimura, J.; Kumano, T.; Takahata, T.; Kudo, H.; Tsuchida, S. Decreased expression of the peroxisomal bifunctional enzyme and carbonyl reductase in human hepatocellular carcinomas. J. Cancer Res. Clin. Oncol., 1999, 125(2), 83-88. (Pubitemid 29161459)
29. Takenaka, K.; Ogawa, E.; Oyanagi, H.; Wada, H.; Tanaka, F. Carbonyl reductase expression and its clinical significance in nonsmall-cell lung cancer. Cancer Epidemiol. Biomarkers Prev., 2005, 14(8), 1972-1975. (Pubitemid 41161209)
30. Umemoto, M.; Yokoyama, Y.; Sato, S.; Tsuchida, S.; Al-Mulla, F.; Saito, Y. Carbonyl reductase as a significant predictor of survival and lymph node metastasis in epithelial ovarian cancer. Br. J. Cancer, 2001, 85(7), 1032-1036. (Pubitemid 33016006)
31. Schlager, J. J.; Powis, G. Cytosolic NAD (P) H: (quinoneacceptor) oxidoreductase in human normal and tumor tissue: effects of cigarette smoking and alcohol. Int. J. Cancer, 1990, 45(3), 403-409. (Pubitemid 20087182)
32. Lopez de, C. A.; Marin, A.; Idoate, M. A.; Tunon, M. T.; Bello, J. Carbonyl reductase and NADPH cytochrome P450 reductase activities in human tumoral versus normal tissues. Eur. J. Cancer, 1999, 35(2), 320-324. (Pubitemid 29136786)
33. Ris, M. M.; von Wartburg, J. P. Heterogeneity of NADPH-dependent aldehyde reductase from human and rat brain. Eur. J. Biochem., 1973, 37(1), 69-77.
34. Bohren, K. M.; Bullock, B.; Wermuth, B.; Gabbay, K. H. The aldoketo reductase superfamily. cDNAs and deduced amino acid sequences of human aldehyde and aldose reductases. J. Biol. Chem., 1989, 264(16), 9547-9551.
35. Wermuth, B.; Bohren, K. M.; Heinemann, G.; von Wartburg, J. P.; Gabbay, K. H. Human carbonyl reductase. Nucleotide sequence analysis of a cDNA and amino acid sequence of the encoded protein. J. Biol. Chem., 1988, 263(31), 16185-16188. (Pubitemid 18262034)
36. Forrest, G. L.; Gonzalez, B. Carbonyl reductase. Chem. Biol. Interact., 2000, 129 (1-2), 21-40. (Pubitemid 32061052)
37. Sciotti, M. A.; Nakajin, S.; Wermuth, B.; Baker, M. E. Mutation of threonine-241 to proline eliminates autocatalytic modification of human carbonyl reductase. Biochem. J., 2000, 350 Pt 1, 89-92.
38. Wermuth, B.; Bohren, K. M.; Ernst, E. Autocatalytic modification of human carbonyl reductase by 2-oxocarboxylic acids. FEBS Lett., 1993, 335(2), 151-154. (Pubitemid 23350397)
39. Krook, M.; Ghosh, D.; Stromberg, R.; Carlquist, M.; Jornvall, H. Carboxyethyllysine in a protein: native carbonyl reductase/NADP (+)-dependent prostaglandin dehydrogenase. Proc. Natl. Acad. Sci. U. S. A, 1993, 90(2), 502-506. (Pubitemid 23028891)
40. Wirth, H.; Wermuth, B. Immunohistochemical localization of carbonyl reductase in human tissues. J. Histochem. Cytochem., 1992, 40(12), 1857-1863.
41. Wermuth, B.; Platts, K. L.; Seidel, A.; Oesch, F. Carbonyl reductase provides the enzymatic basis of quinone detoxication in man. Biochem. Pharmacol., 1986, 35(8), 1277-1282. (Pubitemid 16037035)
42. Kelner, M. J.; Estes, L.; Rutherford, M.; Uglik, S. F.; Peitzke, J. A. Heterologous expression of carbonyl reductase: demonstration of prostaglandin 9-ketoreductase activity and paraquat resistance. Life Sci., 1997, 61(23), 2317-2322. (Pubitemid 27497205)
43. Rady-Pentek, P.; Mueller, R.; Tang, B. K.; Kalow, W. Interindividual variation in the enzymatic 15-keto-reduction of 13, 14-dihydro-15-keto- prostaglandin E1 in human liver and in human erythrocytes. Eur. J. Clin. Pharmacol., 1997, 52(2), 147-153. (Pubitemid 27239600)
44. Gonzalez-Covarrubias, V.; Zhang, J.; Kalabus, J. L.; Relling, M. V.; Blanco, J. G. Pharmacogenetics of human carbonyl reductase 1 (CBR1) in livers from black and white donors. Drug Metab. Dispos., 2009, 37(2), 400-407.
45. Kassner, N.; Huse, K.; Martin, H. J.; Godtel-Armbrust, U.; Metzger, A.; Meineke, I.; Brockmoller, J.; Klein, K.; Zanger, U. M.; Maser, E.; Wojnowski, L. Carbonyl reductase 1 is a predominant doxorubicin reductase in the human liver. Drug Metab. Dispos., 2008, 36(10), 2113-2120.
46. Gonzalez-Covarrubias, V.; Lakhman, S. S.; Forrest, A.; Relling, M. V.; Blanco, J. G. Higher activity of polymorphic NAD (P) H:quinone oxidoreductase in liver cytosols from blacks compared to whites. Toxicol. Lett., 2006, 164(3), 249-258. (Pubitemid 43766794)
47. Lakhman, S. S.; Chen, X.; Gonzalez-Covarrubias, V.; Schuetz, E. G.; Blanco, J. G. Functional characterization of the promoter of human carbonyl reductase 1 (CBR1). Role of XRE elements in mediating the induction of CBR1 by ligands of the aryl hydrocarbon receptor. Mol. Pharmacol., 2007, 72(3), 734-743. (Pubitemid 47347308)
48. Lal, S.; Sandanaraj, E.; Wong, Z. W.; Ang, P. C.; Wong, N. S.; Lee, E. J.; Chowbay, B. CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients. Cancer Sci., 2008, 99(10), 2045-2054.
49. Bains, O. S.; Karkling, M. J.; Lubieniecka, J. M.; Grigliatti, T. A.; Reid, R. E.; Riggs, K. W. Naturally occurring variants of human CBR3 alter anthracycline in vitro metabolism. J. Pharmacol. Exp. Ther., 2010, 332(3), 755-763.
50. Russell, P. T.; Eberle, A. J.; Cheng, H. C. The prostaglandins in clinical medicine. A developing role for the clinical chemist. Clin. Chem., 1975, 21(6), 653-666.
51. Kruger, S.; Schlegel, W. Prostaglandin-E2 9-ketoreductase from human uterine decidua vera. Eur. J. Biochem., 1986, 157(3), 481-485. (Pubitemid 16064200)
52. Basu, S. Novel cyclooxygenase-catalyzed bioactive prostaglandin F2alpha from physiology to new principles in inflammation. Med. Res. Rev., 2007, 27(4), 435-468. (Pubitemid 46991953)
53. Tai, H. H.; Ensor, C. M.; Tong, M.; Zhou, H.; Yan, F. Prostaglandin catabolizing enzymes. Prostaglandins Other Lipid Mediat., 2002, 68-69, 483-493. (Pubitemid 35247416)
54. Lee, S. C.; Levine, L. Prostaglandin metabolism. II. Identification of two 15-hydroxyprostaglandin dehydrogenase types. J. Biol. Chem., 1975, 250(2), 548-552.
55. Iino, T.; Tabata, M.; Takikawa, S.; Sawada, H.; Shintaku, H.; Ishikura, S.; Hara, A. Tetrahydrobiopterin is synthesized from 6-pyruvoyl-tetrahydropterin by the human aldo-keto reductase AKR1 family members. Arch. Biochem. Biophys., 2003, 416(2), 180-187. (Pubitemid 36957843)
56. Musacchio, J. M.; D'Angelo, G. L.; McQueen, C. A. Dihydropteridine reductase: implication on the regulation of catecholamine biosynthesis. Proc. Natl. Acad. Sci. USA, 1971, 68(9), 2087-2091.
57. Tayeh, M. A.; Marletta, M. A. Macrophage oxidation of L-arginine to nitric oxide, nitrite, and nitrate. Tetrahydrobiopterin is required as a cofactor. J. Biol. Chem., 1989, 264(33), 19654-19658. (Pubitemid 20008071)
58. Thony, B.; Auerbach, G.; Blau, N. Tetrahydrobiopterin biosynthesis, regeneration and functions. Biochem. J., 2000, 347 Pt 1, 1-16. (Pubitemid 30199034)
59. Bonafe, L.; Thony, B.; Penzien, J. M.; Czarnecki, B.; Blau, N. Mutations in the sepiapterin reductase gene cause a novel tetrahydrobiopterin-dependent monoamine-neurotransmitter deficiency without hyperphenylalaninemia. Am. J. Hum. Genet., 2001, 69(2), 269-277. (Pubitemid 32695200)
60. Hirakawa, H.; Sawada, H.; Yamahama, Y.; Takikawa, S.; Shintaku, H.; Hara, A.; Mase, K.; Kondo, T.; Iino, T. Expression analysis of the aldo-keto reductases involved in the novel biosynthetic pathway of tetrahydrobiopterin in human and mouse tissues. J. Biochem., 2009, 146(1), 51-60.
61. Monks, T. J.; Hanzlik, R. P.; Cohen, G. M.; Ross, D.; Graham, D. G. Quinone chemistry and toxicity. Toxicol. Appl. Pharmacol., 1992, 112(1), 2-16.
62. Bolton, J. L.; Trush, M. A.; Penning, T. M.; Dryhurst, G.; Monks, T. J. Role of quinones in toxicology. Chem. Res. Toxicol., 2000, 13(3), 135-160. (Pubitemid 30169958)
63. Lamson, D. W.; Plaza, S. M. The anticancer effects of vitamin K. Altern. Med. Rev., 2003, 8(3), 303-318. (Pubitemid 37099889)
64. Shearer, M. J.; Newman, P. Metabolism and cell biology of vitamin K. Thromb. Haemost., 2008, 100(4), 530-547.
65. Thijssen, H. H.; Vervoort, L. M.; Schurgers, L. J.; Shearer, M. J. Menadione is a metabolite of oral vitamin K. Br. J. Nutr., 2006, 95(2), 260-266.
66. Parry, J. D.; Pointon, A. V.; Lutz, U.; Teichert, F.; Charlwood, J. K.; Chan, P. H.; Athersuch, T. J.; Taylor, E. L.; Singh, R.; Luo, J.; Phillips, K. M.; Vetillard, A.; Lyon, J. J.; Keun, H. C.; Lutz, W. K.; Gant, T. W. Pivotal role for two electron reduction in 2, 3-dimethoxy-1, 4-naphthoquinone and 2-methyl-1, 4-naphthoquinone metabolism and kinetics in vivo that prevents liver redox stress. Chem. Res. Toxicol., 2009, 22(4), 717-725.
67. Gong, X.; Gutala, R.; Jaiswal, A. K. Quinone oxidoreductases and vitamin K metabolism. Vitam. Horm., 2008, 78, 85-101.
68. Albano, C. B.; Muralikrishnan, D.; Ebadi, M. Distribution of coenzyme Q homologues in brain. Neurochem. Res., 2002, 27(5), 359-368. (Pubitemid 34579341)
69. Littarru, G. P.; Tiano, L. Bioenergetic and antioxidant properties of coenzyme Q10: recent developments. Mol. Biotechnol., 2007, 37(1), 31-37. (Pubitemid 350135901)
70. Usami, N.; Kitahara, K.; Ishikura, S.; Nagano, M.; Sakai, S.; Hara, A. Characterization of a major form of human isatin reductase and the reduced metabolite. Eur. J. Biochem., 2001, 268(22), 5755-5763. (Pubitemid 33079308)
71. Medvedev, A.; Igosheva, N.; Crumeyrolle-Arias, M.; Glover, V. Isatin: role in stress and anxiety. Stress., 2005, 8(3), 175-183. (Pubitemid 41545954)
72. Manabe, S.; Gao, Q.; Yuan, J.; Takahashi, T.; Ueki, A. Determination of isatin in urine and plasma by high-performance liquid chromatography. J. Chromatogr. B Biomed. Sci. Appl., 1997, 691(1), 197-202. (Pubitemid 27168856)
73. Medvedev, A.; Buneeva, O.; Glover, V. Biological targets for isatin and its analogues: Implications for therapy. Biologics, 2007, 1(2), 151-162.
74. Medvedev, A. E.; Glover, V. Tribulin and endogenous MAO-inhibitory regulation in vivo. Neurotoxicology, 2004, 25 (1-2), 185-192. (Pubitemid 38044180)
75. Wiedemann, K.; Jahn, H.; Kellner, M. Effects of natriuretic peptides upon hypothalamo-pituitary-adrenocortical system activity and anxiety behaviour. Exp. Clin. Endocrinol. Diabetes, 2000, 108(1), 5-13. (Pubitemid 30160429)
76. Cane, A.; Tournaire, M. C.; Barritault, D.; Crumeyrolle-Arias, M. The endogenous oxindoles 5-hydroxyoxindole and isatin are antiproliferative and proapoptotic. Biochem. Biophys. Res. Commun., 2000, 276(1), 379-384.
77. Igosheva, N.; Lorz, C.; O'Conner, E.; Glover, V.; Mehmet, H. Isatin, an endogenous monoamine oxidase inhibitor, triggers a dose-and time-dependent switch from apoptosis to necrosis in human neuroblastoma cells. Neurochem. Int., 2005, 47(3), 216-224. (Pubitemid 40848684)
78. Medvedev, A. E.; Clow, A.; Sandler, M.; Glover, V. Isatin: a link between natriuretic peptides and monoamines? Biochem. Pharmacol., 1996, 52(3), 385-391. (Pubitemid 26233580)
79. Gillam, E. M.; Notley, L. M.; Cai, H.; De Voss, J. J.; Guengerich, F. P. Oxidation of indole by cytochrome P450 enzymes. Biochemistry, 2000, 39(45), 13817-13824.
80. O'Connor, T.; Ireland, L. S.; Harrison, D. J.; Hayes, J. D. Major differences exist in the function and tissue-specific expression of human aflatoxin B1 aldehyde reductase and the principal human aldo-keto reductase AKR1 family members. Biochem. J., 1999, 343 Pt 2, 487-504. (Pubitemid 29511786)
81. Jarabak, J.; Harvey, R. G. Studies on three reductases which have polycyclic aromatic hydrocarbon quinones as substrates. Arch. Biochem. Biophys., 1993, 303(2), 394-401. (Pubitemid 23199838)
82. Jarabak, J. Polycyclic aromatic hydrocarbon quinone-mediated oxidation reduction cycling catalyzed by a human placental NADPH-linked carbonyl reductase. Arch. Biochem. Biophys., 1991, 291(2), 334-338.
83. Atalla, A.; Breyer-Pfaff, U.; Maser, E. Purification and characterization of oxidoreductases-catalyzing carbonyl reduction of the tobacco-specific nitrosamine 4-methylnitrosamino-1-(3-pyridyl)-1-butanone (NNK) in human liver cytosol. Xenobiotica, 2000, 30(8), 755-769.
84. Breyer-Pfaff, U.; Martin, H. J.; Ernst, M.; Maser, E. Enantioselectivity of carbonyl reduction of 4-methylnitrosamino-1-(3-pyridyl)-1-butanone by tissue fractions from human and rat and by enzymes isolated from human liver. Drug Metab Dispos., 2004, 32(9), 915-922. (Pubitemid 39099315)
85. Hecht, S. S. Biochemistry, biology, and carcinogenicity of tobaccospecific N-nitrosamines. Chem. Res. Toxicol., 1998, 11(6), 559-603.
86. Maser, E. 11Beta-hydroxysteroid dehydrogenase responsible for carbonyl reduction of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3- pyridyl)-1-butanone in mouse lung microsomes. Cancer Res., 1998, 58(14), 2996-3003. (Pubitemid 28335078)
87. Maser, E.; Stinner, B.; Atalla, A. Carbonyl reduction of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) by cytosolic enzymes in human liver and lung. Cancer Lett., 2000, 148(2), 135-144. (Pubitemid 30047100)
88. Finckh, C.; Atalla, A.; Nagel, G.; Stinner, B.; Maser, E. Expression and NNK reducing activities of carbonyl reductase and 11betahydroxysteroid dehydrogenase type 1 in human lung. Chem. Biol. Interact., 2001, 130-132 (1-3), 761-773. (Pubitemid 32295861)
89. Breyer-Pfaff, U.; Nill, K. Carbonyl reduction of naltrexone and dolasetron by oxidoreductases isolated from human liver cytosol. J. Pharm. Pharmacol., 2004, 56(12), 1601-1606. (Pubitemid 39602003)
90. Ohara, H.; Miyabe, Y.; Deyashiki, Y.; Matsuura, K.; Hara, A. Reduction of drug ketones by dihydrodiol dehydrogenases, carbonyl reductase and aldehyde reductase of human liver. Biochem. Pharmacol., 1995, 50(2), 221-227.
91. Minotti, G.; Menna, P.; Salvatorelli, E.; Cairo, G.; Gianni, L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev., 2004, 56(2), 185-229. (Pubitemid 38720829)
92. Soldan, M.; Netter, K. J.; Maser, E. Induction of daunorubicin carbonyl reducing enzymes by daunorubicin in sensitive and resistant pancreas carcinoma cells. Biochem. Pharmacol., 1996, 51(2), 117-123. (Pubitemid 26020686)
93. Bains, O. S.; Karkling, M. J.; Grigliatti, T. A.; Reid, R. E.; Riggs, K. W. Two nonsynonymous single nucleotide polymorphisms of human carbonyl reductase 1 demonstrate reduced in vitro metabolism of daunorubicin and doxorubicin. Drug Metab Dispos., 2009, 37(5), 1107-1114.
94. Ax, W.; Soldan, M.; Koch, L.; Maser, E. Development of daunorubicin resistance in tumour cells by induction of carbonyl reduction. Biochem. Pharmacol., 2000, 59(3), 293-300. (Pubitemid 30001756)
95. Plebuch, M.; Soldan, M.; Hungerer, C.; Koch, L.; Maser, E. Increased resistance of tumor cells to daunorubicin after transfection of cDNAs coding for anthracycline inactivating enzymes. Cancer Lett., 2007, 255(1), 49-56. (Pubitemid 47212606)
96. Gonzalez, B.; Akman, S.; Doroshow, J.; Rivera, H.; Kaplan, W. D.; Forrest, G. L. Protection against daunorubicin cytotoxicity by expression of a cloned human carbonyl reductase cDNA in K562 leukemia cells. Cancer Res., 1995, 55(20), 4646-4650.
97. Tanaka, M.; Bateman, R.; Rauh, D.; Vaisberg, E.; Ramachandani, S.; Zhang, C.; Hansen, K. C.; Burlingame, A. L.; Trautman, J. K.; Shokat, K. M.; Adams, C. L. An unbiased cell morphology-based screen for new, biologically active small molecules. PLoS. Biol., 2005, 3(5), e128.
98. Gavelova, M.; Hladikova, J.; Vildova, L.; Novotna, R.; Vondracek, J.; Krcmar, P.; Machala, M.; Skalova, L. Reduction of doxorubicin and oracin and induction of carbonyl reductase in human breast carcinoma MCF-7 cells. Chem. Biol. Interact., 2008, 176(1), 9-18.
99. Klucar, J.; Al-Rubeai, M. G2 cell cycle arrest and apoptosis are induced in Burkitt's lymphoma cells by the anticancer agent oracin. FEBS Lett., 1997, 400(1), 127-130. (Pubitemid 27046835)
100. Forrest, G. L.; Gonzalez, B.; Tseng, W.; Li, X.; Mann, J. Human carbonyl reductase overexpression in the heart advances the development of doxorubicin-induced cardiotoxicity in transgenic mice. Cancer Res., 2000, 60(18), 5158-5164.
101. Olson, L. E.; Bedja, D.; Alvey, S. J.; Cardounel, A. J.; Gabrielson, K. L.; Reeves, R. H. Protection from doxorubicin-induced cardiac toxicity in mice with a null allele of carbonyl reductase 1. Cancer Res., 2003, 63(20), 6602-6606. (Pubitemid 37336434)
102. Salvatorelli, E.; Menna, P.; Cascegna, S.; Liberi, G.; Calafiore, A. M.; Gianni, L.; Minotti, G. Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: implications for cardiotoxicity of doxorubicin-taxane chemotherapies. J. Pharmacol. Exp. Ther., 2006, 318(1), 424-433.
103. Menna, P.; Salvatorelli, E.; Minotti, G. Anthracycline degradation in cardiomyocytes: a journey to oxidative survival. Chem. Res. Toxicol., 2010, 23(1), 6-10.
104. Stewart, D. J.; Grewaal, D.; Green, R. M.; Mikhael, N.; Goel, R.; Montpetit, V. A.; Redmond, M. D. Concentrations of doxorubicin and its metabolites in human autopsy heart and other tissues. Anticancer Res., 1993, 13 (6 A), 1945-1952. (Pubitemid 24036310)
105. Galettis, P.; Boutagy, J.; Ma, D. D. Daunorubicin pharmacokinetics and the correlation with P-glycoprotein and response in patients with acute leukaemia. Br. J. Cancer, 1994, 70(2), 324-329. (Pubitemid 24247158)
106. Bogason, A.; Bhuiyan, H.; Masquelier, M.; Paul, C.; Gruber, A.; Vitols, S. Uptake of anthracyclines in vitro and in vivo in acute myeloid leukemia cells in relation to apoptosis and clinical response. Eur. J. Clin. Pharmacol., 2009, 65(12), 1179-1186.
107. Hempel, G.; Relling, M. V.; de, R. G.; Stary, J.; De, L. P.; Valsecchi, M. G.; Barisone, E.; Boos, J.; Pieters, R. Pharmacokinetics of daunorubicin and daunorubicinol in infants with leukemia treated in the interfant 99 protocol. Pediatr. Blood Cancer, 2010, 54(3), 341-343.
108. Frost, B. M.; Eksborg, S.; Bjork, O.; Abrahamsson, J.; Behrendtz, M.; Castor, A.; Forestier, E.; Lonnerholm, G. Pharmacokinetics of doxorubicin in children with acute lymphoblastic leukemia: multiinstitutional collaborative study. Med. Pediatr. Oncol., 2002, 38(5), 329-337. (Pubitemid 34493112)
109. Gonzalez-Covarrubias, V.; Ghosh, D.; Lakhman, S. S.; Pendyala, L.; Blanco, J. G. A functional genetic polymorphism on human carbonyl reductase 1 (CBR1 V88I) impacts on catalytic activity and NADPH binding affinity. Drug Metab. Dispos., 2007, 35(6), 973-980. (Pubitemid 46798608)
110. Gonzalez-Covarrubias, V.; Kalabus, J. L.; Blanco, J. G. Inhibition of polymorphic human carbonyl reductase 1 (CBR1) by the cardioprotectant flavonoid 7-monohydroxyethyl rutoside (monoHER). Pharm. Res., 2008, 25(7), 1730-1734.
111. Denison, M. S.; Nagy, S. R. Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. Annu. Rev. Pharmacol. Toxicol, 2003, 43, 309-334. (Pubitemid 37372644)
112. Bock, K. W.; Kohle, C. Ah receptor: dioxin-mediated toxic responses as hints to deregulated physiologic functions. Biochem. Pharmacol, 2006, 72(4), 393-404. (Pubitemid 44061741)
113. Huang, Y.; Chan, A. M.; Liu, Y.; Wang, X.; Holbrook, N. J. Serum withdrawal and etoposide induce apoptosis in human lung carcinoma cell line A549 via distinct pathways. Apoptosis, 1997, 2(2), 199-206. (Pubitemid 127505726)
114. Feldman, R.; Luncsford, A.; Heinrikson, R. L.; Westley, J.; Jarabak, J. Glutathione-related inhibition of prostaglandin metabolism. Arch. Biochem. Biophys., 1981, 211(1), 375-381. (Pubitemid 12208351)
115. Chung, H.; Fried, J.; Jarabak, J. Irreversible inhibition of the human placental NADP-linked 15-hydroxyprostaglandin dehydrogenase/9-ketoprostaglandin reductase by glutathione thiosulfonate. Prostaglandins, 1987, 33(3), 391-402. (Pubitemid 17060504)
116. Bateman, R. L.; Rauh, D.; Tavshanjian, B.; Shokat, K. M. Human carbonyl reductase 1 is an S-nitrosoglutathione reductase. J. Biol. Chem., 2008, 283(51), 35756-35762.
117. Tinguely, J. N.; Wermuth, B. Identification of the reactive cysteine residue (Cys227) in human carbonyl reductase. Eur. J. Biochem., 1999, 260(1), 9-14. (Pubitemid 29095689)
118. Gaston, B.; Reilly, J.; Drazen, J. M.; Fackler, J.; Ramdev, P.; Arnelle, D.; Mullins, M. E.; Sugarbaker, D. J.; Chee, C.; Singel, D. J.;. Endogenous nitrogen oxides and bronchodilator S-nitrosothiols in human airways. Proc. Natl. Acad. Sci. USA, 1993, 90(23), 10957-10961. (Pubitemid 23354347)
119. Foster, M. W.; McMahon, T. J.; Stamler, J. S. S-nitrosylation in health and disease. Trends Mol. Med., 2003, 9(4), 160-168. (Pubitemid 36626705)
120. Foster, M. W.; Hess, D. T.; Stamler, J. S. Protein S-nitrosylation in health and disease: a current perspective. Trends Mol. Med., 2009, 15(9), 391-404.
121. Ellis, E. M. Reactive carbonyls and oxidative stress: potential for therapeutic intervention. Pharmacol. Ther., 2007, 115(1), 13-24. (Pubitemid 46990552)
122. Shapiro, H. K. Carbonyl-trapping therapeutic strategies. Am. J. Ther., 1998, 5(5), 323-353. (Pubitemid 28470921)
123. Lee, S. H.; Blair, I. A. Characterization of 4-oxo-2-nonenal as a novel product of lipid peroxidation. Chem. Res. Toxicol, 2000, 13(8), 698-702. (Pubitemid 30663446)
124. Doorn, J. A.; Maser, E.; Blum, A.; Claffey, D. J.; Petersen, D. R. Human carbonyl reductase catalyzes reduction of 4-oxonon-2-enal. Biochemistry, 2004, 43(41), 13106-13114. (Pubitemid 39366059)
125. Martin, H. J.; Maser, E. Role of human aldo-keto-reductase AKR1B10 in the protection against toxic aldehydes. Chem. Biol. Interact., 2009, 178 (1-3), 145-150.
126. Doorn, J. A.; Srivastava, S. K.; Petersen, D. R. Aldose reductase catalyzes reduction of the lipid peroxidation product 4-oxonon-2-enal. Chem. Res. Toxicol, 2003, 16(11), 1418-1423. (Pubitemid 37474091)
127. Smigielska-Kuzia, J.; Sobaniec, W.; Kulak, W.; Zawada, B.; Paszko, G.; Boćkowski, L. Antioxidant enzymes and lipid peroxides in children with Down syndrome. J. Pediatr. Neurol, 2007, 5(2), 117-120. (Pubitemid 47023345)
128. Lin, D.; Lee, H. G.; Liu, Q.; Perry, G.; Smith, M. A.; Sayre, L. M. 4-Oxo-2-nonenal is both more neurotoxic and more protein reactive than 4-hydroxy-2-nonenal. Chem. Res. Toxicol, 2005, 18(8), 1219-1231. (Pubitemid 41170246)
129. Cheon, M. S.; Dierssen, M.; Kim, S. H.; Lubec, G. Protein expression of BACE1, BACE2 and APP in Down syndrome brains. Amino Acids, 2008, 35(2), 339-343.
130. Cheon, M. S.; Shim, K. S.; Kim, S. H.; Hara, A.; Lubec, G. Protein levels of genes encoded on chromosome 21 in fetal Down syndrome brain: Challenging the gene dosage effect hypothesis (Part IV). Amino. Acids, 2003, 25(1), 41-47. (Pubitemid 36930211)
131. Lemieux, N.; Malfoy, B.; Forrest, G. L. Human carbonyl reductase (CBR) localized to band 21q22.1 by high-resolution fluorescence in situ hybridization displays gene dosage effects in trisomy 21 cells. Genomics, 1993, 15(1), 169-172. (Pubitemid 23079585)
132. Sinet, P. M. Metabolism of oxygen derivatives in down's syndrome. Ann. N. Y. Acad. Sci., 1982, 396, 83-94. (Pubitemid 13073498)
133. Bang-Berthelsen, C.; Bergholdt, R.; Heding, P.; Nerup, J.; Pociot, F. The role of CBR1 in the pathogenesis of type 1 diabetes. 2006; pp. 254-255.
134. Bergholdt, R.; Karlsen, A. E.; Hagedorn, P. H.; Aalund, M.; Nielsen, J. H.; Kruhoffer, M.; Orntoft, T.; Wang, H.; Wollheim, C. B.; Nerup, J.; Pociot, F. Transcriptional profiling of type 1 diabetes genes on chromosome 21 in a rat beta-cell line and human pancreatic islets. Genes Immun., 2007, 8(3), 232-238. (Pubitemid 46672056)
135. Kajihara-Kano, H.; Hayakari, M.; Satoh, K.; Tomioka, Y.; Mizugaki, M.; Tsuchida, S. Characterization of S-hexylglutathionebinding proteins of human hepatocellular carcinoma: separation of enoyl-CoA isomerase from an Alpha class glutathione transferase form. Biochem. J., 1997, 328 (Pt 2), 473-478. (Pubitemid 27515588)
136. Ben-Av, P.; Crofford, L. J.; Wilder, R. L.; Hla, T. Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: a potential mechanism for inflammatory angiogenesis. FEBS Lett., 1995, 372(1), 83-87.
137. Jain, S.; Chakraborty, G.; Raja, R.; Kale, S.; Kundu, G. C. Prostaglandin E2 regulates tumor angiogenesis in prostate cancer. Cancer Res., 2008, 68(19), 7750-7759.
138. Sheng, H.; Shao, J.; Morrow, J. D.; Beauchamp, R. D.; DuBois, R. N. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res., 1998, 58(2), 362-366. (Pubitemid 28047080)
139. Makrilia, N.; Lappa, T.; Xyla, V.; Nikolaidis, I.; Syrigos, K. The role of angiogenesis in solid tumours: an overview. Eur. J. Intern. Med., 2009, 20(7), 663-671.
140. Watanabe, K.; Sugawara, C.; Ono, A.; Fukuzumi, Y.; Itakura, S.; Yamazaki, M.; Tashiro, H.; Osoegawa, K.; Soeda, E.; Nomura, T. Mapping of a novel human carbonyl reductase, CBR3, and ribosomal pseudogenes to human chromosome 21q22.2. Genomics, 1998, 52(1), 95-100. (Pubitemid 28452175)
141. Oppermann, U.; Filling, C.; Hult, M.; Shafqat, N.; Wu, X.; Lindh, M.; Shafqat, J.; Nordling, E.; Kallberg, Y.; Persson, B.; Jornvall, H. Short-chain dehydrogenases/reductases (SDR): the 2002 update. Chem. Biol. Interact., 2003, 143-144, 247-253. (Pubitemid 36253589)
142. Filling, C.; Berndt, K. D.; Benach, J.; Knapp, S.; Prozorovski, T.; Nordling, E.; Ladenstein, R.; Jornvall, H.; Oppermann, U. Critical residues for structure and catalysis in short-chain dehydrogenases/reductases. J Biol. Chem., 2002, 277(28), 25677-25684. (Pubitemid 34959957)
143. Zhou, T.; Enyeart, P. J.; Wilke, C. O. Detecting clusters of mutations. PLoS. One, 2008, 3(11), e3765.
144. Jornvall, H.; Persson, B.; Du Bois, G. C.; Lavers, G. C.; Chen, J. H.; Gonzalez, P.; Rao, P. V.; Zigler, J. S., Jr. Zeta-crystallin versus other members of the alcohol dehydrogenase super-family. Variability as a functional characteristic. FEBS Lett., 1993, 322(3), 240-244. (Pubitemid 23144696)
145. Mizobuchi, H.; Miura, T.; Tsujikawa, K.; Nishinaka, T.; Terada, T. Expression of Carbonyl Reductases in Fetal Human Brain, but Not in Adult. Purdue University Press: West Lafayette, Indiana, 2007; pp 368-378.
146. Lakhman, S. S.; Ghosh, D.; Blanco, J. G. Functional significance of a natural allelic variant of human carbonyl reductase 3 (CBR3). Drug Metab. Dispos., 2005, 33(2), 254-257. (Pubitemid 40220348)
147. Blanco, J. G.; Leisenring, W. M.; Gonzalez-Covarrubias, V. M.; Kawashima, T. I.; Davies, S. M.; Relling, M. V.; Robison, L. L.; Sklar, C. A.; Stovall, M.; Bhatia, S. Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD (P) H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer. Cancer, 2008, 112(12), 2789-2795. (Pubitemid 351969225)
148. Zhang, J.; Blanco, J. G. Identification of the promoter of human carbonyl reductase 3 (CBR3) and impact of common promoter polymorphisms on hepatic CBR3 mRNA expression. Pharm. Res., 2009, 26(9), 2209-2215.
149. Fan, L.; Goh, B. C.; Wong, C. I.; Sukri, N.; Lim, S. E.; Tan, S. H.; Guo, J. Y.; Lim, R.; Yap, H. L.; Khoo, Y. M.; Iau, P.; Lee, H. S.; Lee, S. C. Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicity. Pharmacogenet. Genomics, 2008, 18(7), 621-629.
150. Choi, J. Y.; Barlow, W. E.; Albain, K. S.; Hong, C. C.; Blanco, J. G.; Livingston, R. B.; Davis, W.; Rae, J. M.; Yeh, I. T.; Hutchins, L. F.; Ravdin, P. M.; Martino, S.; Lyss, A. P.; Osborne, C. K.; Abeloff, M. D.; Hayes, D. F.; Ambrosone, C. B. Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial. Clin. Cancer Res., 2009, 15(16), 5258-5266.
151. Wierstra, I. Sp1: emerging roles-beyond constitutive activation of TATA-less housekeeping genes. Biochem. Biophys. Res. Commun., 2008, 372(1), 1-13.
152. Garattini, E.; Gianni, M.; Terao, M. Retinoids as differentiating agents in oncology: a network of interactions with intracellular pathways as the basis for rational therapeutic combinations. Curr. Pharm. Des, 2007, 13(13), 1375-1400. (Pubitemid 46758854)
153. Glover, L. A.; Lindsay, J. G. Targeting proteins to mitochondria: a current overview. Biochem. J., 1992, 284 (Pt 3), 609-620.
154. Wu, K.; Knox, R.; Sun, X. Z.; Joseph, P.; Jaiswal, A. K.; Zhang, D.; Deng, P. S.; Chen, S. Catalytic properties of NAD (P) H:quinone oxidoreductase-2 (NQO2), a dihydronicotinamide riboside dependent oxidoreductase. Arch. Biochem. Biophys., 1997, 347(2), 221-228. (Pubitemid 27492792)
155. Chan, P. H. Mitochondrial dysfunction and oxidative stress as determinants of cell death/survival in stroke. Ann. N. Y. Acad. Sci., 2005, 1042, 203-209. (Pubitemid 40967640)